PMV Pharmaceuticals (PMVP) vs Unicycive Therapeutics (UNCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PMV Pharmaceuticals (PMVP) has outperformed Unicycive Therapeutics (UNCY) over the past year, gaining 4.9% versus a loss of 14.7%. Over five years, UNCY leads with a -85.1% price change compared with -93.8% for PMVP. PMV Pharmaceuticals is the larger company by market cap ($117.8 million vs $113.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PMVP | UNCY |
|---|---|---|
| Share price | $1.56 | $4.15 |
| Market cap | $117.80M | $113.54M |
| 1-day change | +4.70% | +1.84% |
| YTD return | +19.20% | -29.46% |
| 1-year return | +4.93% | -14.68% |
| 5-year return | -93.78% | -85.06% |
| Forward P/E | — | 2.46 |
| EPS (TTM) | $-1.42 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.91 | $8.74 |
| 52-week low | $1.02 | $3.93 |
| Distance from 52-week high | -18.32% | -52.57% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +169.23% | +585.16% |
| Average volume | 661.39K | 839.29K |
| Shares outstanding | 75.51M | 27.39M |
| Employees | 54 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PMVP has outperformed UNCY by 19.6 percentage points over the past year.
About PMV Pharmaceuticals
PMVP stock →PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 54 employees
About Unicycive Therapeutics
UNCY stock →Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
PMVP vs UNCY FAQ
Which is bigger, PMV Pharmaceuticals or Unicycive Therapeutics?
PMV Pharmaceuticals (PMVP) is larger, with a market capitalization of $117.80M compared with $113.54M for Unicycive Therapeutics (UNCY).
Which stock has performed better over the past year, PMVP or UNCY?
PMVP returned +4.93% over the past 12 months, compared with -14.68% for UNCY (price return, excluding dividends). Past performance does not predict future results.
Are PMV Pharmaceuticals and Unicycive Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.